Co Diagnostics, Inc. CODX
We take great care to ensure that the data presented and summarized in this overview for Co-Diagnostics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CODX
View all-
Vanguard Group Inc Valley Forge, PA1.78MShares$1.3 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny568KShares$414,4370.0% of portfolio
-
Black Rock Inc. New York, NY502KShares$366,4780.0% of portfolio
-
Geode Capital Management, LLC Boston, MA321KShares$234,5300.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX273KShares$199,2170.01% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA188KShares$136,9250.0% of portfolio
-
Kestra Advisory Services, LLC128KShares$93,3960.0% of portfolio
-
State Street Corp Boston, MA101KShares$73,4720.0% of portfolio
-
Koss Olinger Consulting, LLC58.1KShares$42,4140.01% of portfolio
-
Northern Trust Corp Chicago, IL55KShares$40,1330.0% of portfolio
Latest Institutional Activity in CODX
Top Purchases
Top Sells
About CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Insider Transactions at CODX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 23
2024
|
Richard S Serbin |
BUY
Grant, award, or other acquisition
|
Direct |
48,333
+22.57%
|
-
|
Nov 23
2024
|
James B Nelson |
BUY
Grant, award, or other acquisition
|
Direct |
48,333
+22.83%
|
-
|
Nov 23
2024
|
Eugene Durenard |
BUY
Grant, award, or other acquisition
|
Direct |
48,333
+22.83%
|
-
|
Nov 23
2024
|
Ted Murphy |
BUY
Grant, award, or other acquisition
|
Direct |
48,333
+21.56%
|
-
|
Nov 23
2024
|
Dwight H Egan Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
49,689
-8.68%
|
$49,689
$1.01 P/Share
|
Nov 23
2024
|
Dwight H Egan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
163,333
+22.2%
|
-
|
Nov 23
2024
|
Richard David Abbott President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,085
-30.43%
|
$6,085
$1.01 P/Share
|
Nov 23
2024
|
Richard David Abbott President |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
Nov 23
2024
|
Brian Lee Brown Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,816
-8.86%
|
$40,816
$1.01 P/Share
|
Nov 23
2024
|
Brian Lee Brown Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
134,167
+22.55%
|
-
|
May 23
2024
|
Eugene Durenard |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.69%
|
-
|
May 23
2024
|
James B Nelson |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.69%
|
-
|
May 23
2024
|
Richard S Serbin |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.34%
|
-
|
May 23
2024
|
Ted Murphy |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+19.05%
|
-
|
May 23
2024
|
Dwight H Egan Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
42,008
-10.27%
|
$42,008
$1.09 P/Share
|
May 23
2024
|
Dwight H Egan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
138,333
+25.26%
|
-
|
May 23
2024
|
Brian Lee Brown Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
35,865
-10.98%
|
$35,865
$1.09 P/Share
|
May 23
2024
|
Brian Lee Brown Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
113,334
+25.76%
|
-
|
Nov 23
2023
|
James B Nelson |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+26.09%
|
-
|
Nov 23
2023
|
Richard S Serbin |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+25.53%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 882K shares |
---|
Sale (or disposition) back to the issuer | 174K shares |
---|